Literature DB >> 8804339

Correction of congenital erythropoietic porphyria by bone marrow transplantation.

C Thomas1, C Ged, Y Nordmann, H de Verneuil, I Pellier, A Fischer, S Blanche.   

Abstract

Congenital erythropoietic porphyria (Gunther disease) is a rare metabolic disorder caused by uroporphyrinogen III synthetase deficiency. We report the case of a 2-year-old girl with a severe form of this disease who received HLA-identical bone marrow transplantation from her heterozygous sister. Two transplantations were necessary to obtain full hematopoietic chimerism. Correction of the enzyme deficiency was confirmed by measuring erythrocyte uroporphyrinogen III synthetase activity. The patient's clinical condition improved dramatically, and she is well 1 year after the second transplantation, with no further treatment. Although long-term efficacy remains to be confirmed, we conclude that allogeneic bone marrow transplantation can cure patients with congenital erythropoietic porphyria.

Entities:  

Mesh:

Year:  1996        PMID: 8804339     DOI: 10.1016/s0022-3476(96)70082-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria.

Authors:  Daniel N Egan; Zhantao Yang; John Phillips; Janis L Abkowitz
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

2.  Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

Authors:  F Mazurier; F Moreau-Gaudry; S Salesse; C Barbot; C Ged; J Reiffers; H de Verneuil
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

3.  Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes.

Authors:  David F Bishop; Sonia Clavero; Narla Mohandas; Robert J Desnick
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

Review 4.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

5.  Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease).

Authors:  Sophie Dupuis-Girod; Véronique Akkari; Cécile Ged; Claire Galambrun; Kamila Kebaïli; Jean-Charles Deybach; Alain Claudy; Lucette Geburher; Noël Philippe; Hubert de Verneuil; Yves Bertrand
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

6.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 7.  Congenital erythropoietic porphyria: Recent advances.

Authors:  Angelika L Erwin; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-12-27       Impact factor: 4.797

8.  Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells.

Authors:  Florence Prat; Jérôme Toutain; Julian Boutin; Samuel Amintas; Grégoire Cullot; Magalie Lalanne; Isabelle Lamrissi-Garcia; Isabelle Moranvillier; Emmanuel Richard; Jean-Marc Blouin; Sandrine Dabernat; François Moreau-Gaudry; Aurélie Bedel
Journal:  Stem Cell Reports       Date:  2020-08-13       Impact factor: 7.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.